Close
FINDING CURES TOGETHER<sup>SM</sup>
Adam P. Dicker, MD, PhD

Adam P. Dicker, MD, PhD
Chair, Department of Radiation Oncology
Jefferson Medical College of Thomas Jefferson University​
Philadelphia, Pennsylvania

​Dr. Adam P. Dicker is chair and professor of radiation oncology, pharmacology and experimental therapeutics at Thomas Jefferson University. Dr. Dicker leads the radiation research and translational biology program at the Kimmel Cancer Center at Thomas Jefferson University. In addition, he serves as director of the Christine Baxter Research Laboratory for Experimental Cancer Therapies at Jefferson Medical College. His laboratory has utilized zebrafish as a new model to study radiation response in whole organism. They have characterized the baseline gene expression profile of zebrafish at various stages of development using a species-specific microarray to assess genetic modulation following exposure to radiation both in the presence or absence of radiomodifying agents. His work in prostate cancer, funded by the Department of Defense and the Prostate Cancer Foundation focuses on the “self-seeding” of prostate cells with metastatic properties back to the site of origin, which contributes to disease progression. Dr. Dicker has also received funding for prostate cancer from the Department of Defense, exploring the use of “smart needles”. Dr. Dicker has been a principal investigator in a significant number of “first in human” developmental therapeutic trials involving novel signal transduction agents and radiation therapy. He and his colleagues at Jefferson have developed new approaches to radiation therapy for the treatment of cancer, and have successfully applied their findings from the laboratory to the clinical setting.

Dr. Dicker serves as the chair of the Translational Research Program in the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cooperative group. He served as chair of the Radiation and Cancer Biology Committee of the American Society of Therapeutic Radiation Oncology. Dr. Dicker represents the RTOG on the National Cancer Institute’s Investigational Drug Steering Committee of Cancer Treatment Evaluation Program and also serves as a consultant on cancer to the European Commission, the National Cancer Institute of Canada and the Italian Association of Cancer Research. He has published extensively on prostate brachytherapy, image guided radiotherapy and use of preclinical model systems for drug development and has more than 160 peer-reviewed journal articles and chapters. Dr. Dicker serves on numerous ASTRO and ASCO committees and on the editorial boards of Clinical Cancer Research, Cancer Biology, BMC Cancer, Frontiers in Radiation Oncology and Radiation Oncology.